Abstract
Deregulation of the PI3K-Akt-mTOR pathway is unanimously pragmatic in a number of tumors. This pathway pedals proliferation, survival, translation, and coupled with tumorassociated endurance. Current efforts focus on the discovery and development of novel inhibitors of this pathway. We have discovered6-(4-phenoxyphenyl)-N-phenylquinolin-4-amine [PQQ] as a potent mTOR inhibitor with IC50 value of 64nM in a cell-based and cell-free mTOR assay. Mechanistically, PQQ was found to be a strong PI3K-Akt-mTOR-p70S6K cascade inhibitor in Human promyelocytic leukemia HL-60 cells. Moreover, it was found to be dual mTORC1 and mTORC2 inhibitor that inhibit the entire mTOR kinase-dependent functions and feedback commencement of PI3K/Akt pathway. PQQ simultaneously induces apoptosis via mitochondrial dependant pathway, which was confirmed through a battery of the assays, e.g. cellular and nuclear microscopy, annexin-V assay, cell cycle analysis and loss of mitochondrial membrane potential. In summary, PQQ discovered as a novel secondgeneration mTOR inhibitor with significant cytotoxic and apoptotic potentials. Thus, it might be a significant lead structure for the development of mTOR-targeted based anti-cancer therapeutics.
Keywords: Apoptosis, 6-(4-phenoxyphenyl)-N-phenylquinolin-4-amine [PQQ], PI3K-Akt-mTOR.
Anti-Cancer Agents in Medicinal Chemistry
Title:A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells
Volume: 15 Issue: 10
Author(s): Suresh Kumar, Santosh Kumar Guru, Vunnam Venkateswarlu, Fayaz Malik, Ram A. Vishwakarma, Sanghapal D. Sawant and Shashi Bhushan
Affiliation:
Keywords: Apoptosis, 6-(4-phenoxyphenyl)-N-phenylquinolin-4-amine [PQQ], PI3K-Akt-mTOR.
Abstract: Deregulation of the PI3K-Akt-mTOR pathway is unanimously pragmatic in a number of tumors. This pathway pedals proliferation, survival, translation, and coupled with tumorassociated endurance. Current efforts focus on the discovery and development of novel inhibitors of this pathway. We have discovered6-(4-phenoxyphenyl)-N-phenylquinolin-4-amine [PQQ] as a potent mTOR inhibitor with IC50 value of 64nM in a cell-based and cell-free mTOR assay. Mechanistically, PQQ was found to be a strong PI3K-Akt-mTOR-p70S6K cascade inhibitor in Human promyelocytic leukemia HL-60 cells. Moreover, it was found to be dual mTORC1 and mTORC2 inhibitor that inhibit the entire mTOR kinase-dependent functions and feedback commencement of PI3K/Akt pathway. PQQ simultaneously induces apoptosis via mitochondrial dependant pathway, which was confirmed through a battery of the assays, e.g. cellular and nuclear microscopy, annexin-V assay, cell cycle analysis and loss of mitochondrial membrane potential. In summary, PQQ discovered as a novel secondgeneration mTOR inhibitor with significant cytotoxic and apoptotic potentials. Thus, it might be a significant lead structure for the development of mTOR-targeted based anti-cancer therapeutics.
Export Options
About this article
Cite this article as:
Kumar Suresh, Guru Kumar Santosh, Venkateswarlu Vunnam, Malik Fayaz, Vishwakarma A. Ram, Sawant D. Sanghapal and Bhushan Shashi, A Novel Quinoline Based Second-generation mTOR Inhibitor that Induces Apoptosis and Disrupts PI3K-Akt-mTOR Signaling in Human Leukemia HL-60 Cells, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (10) . https://dx.doi.org/10.2174/1871520615666150402093558
DOI https://dx.doi.org/10.2174/1871520615666150402093558 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Metalloenzymes and Cancer: Μetalloenzyme Ιnhibitors and Artificial Metalloenzymes as anti-cancer agents
Metalloenzymes are enzymes containing metal ions, which are directly bound to the enzyme and play a role in promoting catalysis. About one-third of all enzymes known so far are metalloenzymes [1]. Metalloenzymes are central to a wide range of essential biological activities, including nucleic acid modification, protein degradation, and many ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combinatorial Application of Nucleic Acid-Based Agents Targeting Protein Kinases for Cancer Treatment
Current Pharmaceutical Design Microarray Analysis of Human Epithelial Cell Responses to Bacterial Interaction
Infectious Disorders - Drug Targets Melatonin in the Biliary Tract and Liver: Health Implications
Current Pharmaceutical Design Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Peptides and Small Molecules Targeting the Plasminogen Activation System: Towards Prophylactic Anti-Metastasis Drugs for Breast Cancer
Recent Patents on Anti-Cancer Drug Discovery Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry Cancer Prevention with Promising Natural Products: Mechanisms of Action and Molecular Targets
Anti-Cancer Agents in Medicinal Chemistry The Type II Transmembrane Serine Protease, Matriptase-2: Possible Links to Cancer?
Anti-Cancer Agents in Medicinal Chemistry Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Current Medicinal Chemistry HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Opioids and Cannabinoids Interactions: Involvement in Pain Management
Current Drug Targets The Potential Therapeutic Impact of Metformin in Glioblastoma Multiforme
Current Medicinal Chemistry Radiopharmaceuticals in Tumor Hypoxia Imaging: A Review Focused on Medicinal Chemistry Aspects
Anti-Cancer Agents in Medicinal Chemistry Targeting Glycosylation Aberrations to Improve the Efficiency of Cancer Phototherapy
Current Cancer Drug Targets Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets Focus on the Multimodal Role of Biomarkers in Breast Cancer
Current Pharmaceutical Design Modulators of Protein-Protein Interactions – Novel Approaches in Targeting Protein Kinases and Other Pharmaceutically Relevant Biomolecules
Current Topics in Medicinal Chemistry Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Molecular Mechanisms of the Action of Myricetin in Cancer
Mini-Reviews in Medicinal Chemistry